logoCatch innovation invests in promising new therapies, and accelerates their progress by actively supporting young companies to achieve clinical proof of concept with their lead programs. Catch Innovation has a team of professionals who accompany the programs closely and provide hands-on support.




The introduction of new ideas, methods, or invention.


The quality of being honest and of always having high moral principles.


Being responsible for the effects of your actions, and being willing to explain or be criticized for them.

Our Mission

  • To contribute to the enrichment of quality of life around the world through the creation of innovative treatments addressing diverse medical needs.

Our Vision

  • Through strategic investment in people, ideas and partnerships essential to outstanding research in the strategic areas we built innovative products changing Standard of Care.
  • Find the shortest route between Idea and Patient
  • To realize shareholders’ value through highly efficient management

Paul Stolk


Mr Stolk arrived to Hungary in the early nineties as a student in technology from Holland. His curiosity to see new cultures and market developments made him stay in Hungary. His passion is to get from an idea to a workable company that has a base to grow and further develop. Until now he managed successful start-ups in the pharmaceutical-, communication- and information technology- industry.
Next to the last 20 years of international investment management and business development experience he has proven his expertise on transforming concepts into products (e.g. Despharma product range– product being sold in 55 countries worldwide
Next to his work he is an active board member of the Dutch Hungarian chamber of commerce ( In his free time he spends time with his wife and three daughters, sailing, golf and mountain biking.


Balazs Janki


Balazs Janki has 20 years business experience. He is an entrepreneur and investor in early startups. He has expertise in managing regulatory processes for medical devices and invitro diagnostics, implementing, quality system, guiding research activities. Further he has guided clinical trials to completion, offering operational management. He has strong skills in project management and process implementation (Despharma, Noviomeditas, Hungarian Academi of Science, University of Pannonia).


Marton Szigeti

PhD student

BSc (bio engineering)

MSc (environmental engineering)

Mr. Szigeti received his BSc in 2013 in Bilogical Engineering and MSc in 2014 in Environmental Engineering from University of Pannonia. Presently he study of Enviromental Engineering MSc. at University of Pannonia. He is a PhD student of MTA-PE Translational Glycomics Research Group, working at University of Pannonia. His current research interest focuses on molecular biology, fluorescent microscopy, capillary electrophoresis, PCR and analytics. 


Dr. Gabor Jarvas

MSc (chemical engineering)

PhD (chemistry)

Dr. Jarvas received his MSc in 2007 in Chemical Engineering and his PhD in 2012 in chemistry from University of Pannonia. He is a postdoctoral researcher of MTA-PE Translational Glycomics Research Group, working at University of Pannonia. His current research interest focuses on the CFD simulation and application of Microfabriacated Analytical Devices for the identification of biomarkers of cancer in early phase. He has published two peer review papers in international journals. He is also active in the estimation of phase equilibrium of multicomponent mixtures using COSMO-RS theory.


Advisory board

Prof. Andras Guttman

PhD (chemical engineering)

Doctor of Hungarian Academy of Science (technology)

Prof. Guttman leads the Horváth Laboratory of Bioseparation Sciences (University of Debrecen, Hungary) established with the help of his Marie Curie Chair from the European Commission to pursue basic research in the field of bioseparation sciences with the aim to develop and implement high performance bioanalytical techniques for proteomics and glycomics based biomarker discovery using single- and multi-dimensional separation methods. Dr Guttman is an adjunct professor at the Barnett Institute (Northeastern University, Boston, USA). Prior to forming HLBS, Dr. Guttman held appointments at Diversa Corporation (San Diego, CA) implementing bioindustrial scale carbohydrate analysis methods; at the Torrey Mesa Research Institute (La Jolla, CA) applying microfluidics methods to large scale genotyping; Genetic BioSystems (San Diego, CA), working on a novel microgel electrophoresis platform; and at Beckman Coulter (Fullerton, CA) developing capillary electrophoresis kits. In his postdoctoral work at the Barnett Institute (Boston, MA), he conducted basic research in the field of capillary gel electrophoresis. In top 0.5% scientist worldwide – All time Nr 28 in Hungary

Member of the Hungarian Academy of Science since 2004

Publications: 354 publications (327 peer reviewed), 36 book chapters, 6 edited books, 32 grants and 25 patents

Conferences: 391 lectures (>280 invited) and >291 posters in international symposiums and conferences

Citations: >11,500; Cumulative Impact Factor: >1,150; H-index: 53

17 awards

He is the president of the ACS-HU chapter, a Board member of CASSS, and on the editorial boards of numerous international scientific journals. Dr. Guttman graduated from the Veszprem University (Hungary) in chemical engineering, where he also received his doctoral degree. He got the Analytical Chemistry Award of the Hungarian Chemical Society in 2000, the Szentgyorgyi Professorship in 2005, became a member of the Hungarian Academy of Sciences in 2004 and named as a Fulbright Scholar in 2012.


Jozsef Tovari


Jozsef Tovari graduated as a biologist in 1994 at the Eotvos Lorand University in Budapest. He received his Ph.D in 1999. Semmelweis University in Budapest. In the following téma Tumorsejt-extracelluláris mátrix kölcsönhatás szabályozása és befolyásolása az áttétképzés folyamatában. Currently he is Head of Department of Experimental Pharmacology at the National Institute of Oncology in Budapest. His expertise are, Cancer Biology Cell Proliferation and Oncology.


Dr. Tibor Bakacs

M.D., D.Sc., Ph.D.

Dr. Bakacs received his medical degree at the Semmelweis Medical University in Budapest with summa cum laude in 1971. He obtained a post graduate diploma from Clinical Chemistry in 1978 at the Hungarian Post Graduate Medical University. He received his Ph.D. and D.Sc. titles from the Hungarian Academy of Sciences in 1979 and 1986, respectively. Tibor Bakacs worked various periods of time abroad, among others at the Karolinska Institute (Stockholm, Sweden), the Patterson Laboratories (Manchester, UK), the National Cancer Institute (Bethesda, USA), the Cornell University (New York, USA), the University of Cambridge (UK), the UK Transplant Service, Bristol, and the Eidgenössische Technische Hochschule Zürich (ETH, Switzerland). He translated several books from English to Hungarian and has over 70 publications. Currently he is working to improve immune therapy concepts.


Prof. Laszlo Takacs


D.Sc (Medical Biology, Molecular Sciences)

Ph.D. (Immunology)

Prof. Takacs received his Medical Doctor degree at the Semmelweis University in Budapest. He got his PhD. in 1990 in Immunology at the Hungarian Academy of Sciences

Laszlo Takacs is since 1996 a Doctor of Sciences (D.Sc.): in,

Medical Biology, Molecular Sciences, and member of the Hungarian Academy of Science. He is full professor, a part time employee of the Dept. of Human Genetics, Medical faculty of the University of Debrecen. Teaching Responsibility: Founder of the Medical Genome Biology Course (compulsory credited course for 1st year medical students) and the Genome Biology Course for 3rd year molecular biologist (M.Sc program) students, courses are in English and Hungarian, responsibility includes exams. He has several leading positions in reputable institutes and big companies. For 6 years he was Head of Genomics and Bioinformatics at Pfizer Fresnes Laboratories, France, before from 1992 to 1998 he worked at Amgen Inc., Thousand Oaks, California as a Principal investigator. Between 1989 and 1992 he worked at the NIAAA, National Institutes of Health in Rockville, Maryland as Head of Special Unit. He has 11 patents >120 publications. His independent impact >330, independent citation > 1600 (excluding books) in peer reviewed scientific periodicals only, scientometrics data: i10 index= 46, h-index=22. In 1995 he founded and started Biosystems International SAS (France) and BSI Kft (Hungary) a diagnostics R&D company. He serves as CEO from 2005-today.


Prof Shimon Slavin MD

Prof. Slavin is an Israeli professor of medicine. Dr. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for the cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for the induction of transplantation tolerance to bone marrow and donor allografts. More recently, he’s been working on the use of multi-potent mesenchymal stem cell (MSC) for regenerative medicine for the treatment of neurological, systemic, and orthopedic disorders. Dr. Slavin is an author of 4 books, his basic research and clinically applied discoveries were represented in over 600 published articles and more than 900 national and international scientific presentations, which resulted in international impact in several different disciplines mostly related to cellular therapy for treatment of malignant and nonmalignant disorders. Immunotherapy of cancer by donor lymphocytes made it possible to treat otherwise resistant hematological malignancies and certain metastatic solid tumors in patients with multidrug resistant cancer. At present, Slavin operates his new clinic, Biotherapy International, The Center for Innovative Cancer Biotherapy & Regenerative Medicine in Tel Aviv, Israel.


Tamás Bakács


Mr. Bakács has over 10 years of international investment management and financial services experience. He is a well experienced global resource fund manager who was most recently the Managing Director, founder and portfolio manager of the Reálszisztéma Marco Polo Global Equity Fund, a mining focused equity fund based in Budapest, Hungary. Previously, Mr. Bakács worked as a global security analyst and investment manager at Baillie Gifford & Co. in Edinburgh, UK, where he was also head of the firm’s specialist Oil and Gas Sector Group. Most recently, Mr. Bakács was an investment manager at Compass Asset Management JSC in Almaty, Kazakhstan, an emerging markets based hedge fund, focusing on commodity linked equity investments. Mr. Bakács holds a B.S. in Accounting, Summa Cum Laude, from St. Francis College in New York and an MBA with a concentration in Finance from the UCLA Anderson School of Management. In addition, Mr. Bakács is a member of the Advisory Board of Skyharbour Resources (TSX-V: SYH), a preeminent uranium and thorium exploration Company with projects located in the prolific Athabasca Basin of Saskatchewan, Canada.